<SEC-DOCUMENT>0001193125-18-270026.txt : 20180910
<SEC-HEADER>0001193125-18-270026.hdr.sgml : 20180910
<ACCEPTANCE-DATETIME>20180910160507
ACCESSION NUMBER:		0001193125-18-270026
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180910
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180910
DATE AS OF CHANGE:		20180910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		181062793

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d621795d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>September 10, 2018 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Pacific
Biosciences of California, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-34899</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">16-1590339</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1305 O&#146;Brien Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Menlo Park, California 94025 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">521-8000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:71%; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>OTHER EVENTS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 10, 2018, Pacific Biosciences of California, Inc. (the &#147;<U>Company</U>&#148;) issued a press release announcing the
commencement of an underwritten public offering of its common stock pursuant to a shelf registration statement filed on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-219642)</FONT> with the
Securities and Exchange Commission, which was declared effective August&nbsp;18, 2017. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has updated its disclosure regarding its business. The revised disclosure is filed herewith as Exhibit 99.2 and incorporated
herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including the exhibits hereto, shall not
constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, which is being made only by means of a written prospectus meeting the requirements of Section&nbsp;10 of the Securities Act, nor shall there be any
sale of the Company&#146;s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>ITEM&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FINANCIAL STATEMENTS AND EXHIBITS. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d621795dex991.htm">Press Release, dated September 10, 2018. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d621795dex992.htm">Business update. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Pacific Biosciences of California, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Susan K. Barnes</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Susan K. Barnes</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Executive Vice President, Chief Financial Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and Principal Accounting Officer</B></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September 10, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d621795dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g621795g58e15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MENLO PARK, CA, September 10, 2018, Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its
common stock in an underwritten public offering. Pacific Biosciences also intends to grant the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 15% of the number of shares of its common stock sold
in the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC and Cantor Fitzgerald&nbsp;&amp; Co. are acting as the joint book-running managers for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific Biosciences intends to use the net proceeds from the offering for general corporate purposes, including capital expenditures and working capital.
Pacific Biosciences may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although it has no present commitments or agreements
to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement relating to the shares of common stock was previously filed with the Securities and Exchange Commission (the
&#147;SEC&#148;) and declared effective on August&nbsp;18, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC&#146;s website. Copies of the
preliminary prospectus supplement (when available) and accompanying prospectus may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn:&nbsp;Prospectus Department, by
telephone at (631) 592-5973 or by email at PostSaleManualRequests@broadridge.com or Cantor Fitzgerald&nbsp;&amp; Co., Attention:&nbsp;Capital Markets, 499&nbsp;Park Ave., 6th Floor, New York, New York 10022, or by
<FONT STYLE="white-space:nowrap">e-mail</FONT> at prospectus@cantor.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any
such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Pacific Biosciences of California, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pacific
Biosciences offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT&reg;) Technology, Pacific Biosciences&#146; products enable <I>de novo</I> genome assembly to finish
genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel
genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences&#146; technology provides high accuracy, ultra-long reads, uniform coverage,
and the ability to simultaneously detect epigenetic changes. PacBio&reg; sequencing systems, including consumables and software, provide a simple, fast, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT>
workflow for SMRT Sequencing. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Page 2 of 2 </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Safe Harbor&#148; Statement Under the Private Securities Litigation Reform Act of 1995 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that
could cause actual results to differ materially, including, but not limited to, whether or not Pacific Biosciences will be able to raise capital through the sale of shares of common stock or consummate the offering, the final terms of the offering,
the satisfaction of customary closing conditions, prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons, and the impact of general economic,
industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the proposed offering, Pacific Biosciences and its business can be found under the heading &#147;Risk Factors&#148; in Pacific
Biosciences&#146; most recent periodic, quarterly and annual reports filed with the SEC and in the preliminary prospectus supplement and accompanying prospectus relating to the offering to be filed with the SEC. Pacific Biosciences assumes no duty
or obligation to update or revise any forward-looking statements for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Contact: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pacific
Biosciences of California, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1305 O&#146;Brien Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Menlo Park, California 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650)
<FONT STYLE="white-space:nowrap">521-8450</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d621795dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RECENT DEVELOPMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously
disclosed in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> sales in China for the three-month period ended June&nbsp;30, 2018 accounted for approximately 33% of our total revenue, as compared to 26% of our total revenue
for the three-month period ended June&nbsp;30, 2017. To capitalize upon our increasing opportunities in China, we have engaged in ongoing discussions regarding, but have not committed to, entering into strategic transactions with diagnostic and
financing partners in China. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g621795g58e15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g621795g58e15.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M([:SD\9:K&FX-=7NHR?:$T82-L9+?3MDD07:]U+N('DUL=4DVJ3]G!;?S?\
M ^7WG],<+>$&1Y9AZ5?/Z:SC,G[TX.4U@Z3Z1A37(ZW+JG.M>,MU2C9'Q3J?
MQ;^*NLW,EWJ_Q+\?:E<R,7>>^\8>(+F0L?1I=0;: . !@ 8   Q7(ZM1[U)/
M_MY_YGZ50X?R+"P5/#Y+@:$(JRC#"4(K\*:_'<_0;XF?M ?&#X5? #]CCQ-X
M+\<ZO8ZKKOAWXEMXADOVAUR'Q -,UGPK'8KK,&M1727S0175U'%*X\V);B01
M2)NS7=4K5:5#"N$VFU*_6]FK7OV/R3).$N'L]XL\1<%F65TJE#"8C+OJZIWH
M/#^THXIS]C*BX.',XQ<HKW9.*YHNQ];_ ++7[=GA;XRS:/X#\>P0^$OB=<Q"
MWMID"Q>%O%MXF0D>CS2SO+INKS(N[^SKC*R/\MK/*\BP)TX?&1JVA-<M3IV?
MIV?E]S/@..?"W'<-QQ&:95)X_)*;YI1>N)PD.KJI14:E*+T]M#6*UJ0BDYO]
M!*[3\E"@#YJF^('QN\1>/?B/X9^'GAWX5RZ/\/\ 6]&T.2]\9^(O%NF:G>W&
MJ>%]&\1F2.WT/PYJ,'DH-5,0)DC;]U]WN38>B+^B_%KQIH?C[PK\-?BYX-T;
M0]6\;V^N3>$?%/@K7[O7_">J7/AZQ.J:GI5Y'J^DZ;J&BW\.GCS%:6*:*;("
M,"&"&WR"WX&7\.OVB[+QS\4=7\#OI"V7AW5+?5[WX4>+H;@3V/CVT\(:A/H7
MC)H'#;=\&JVT\UH80Z364+S,RD+YIL%K?(ZKQC\3?%#>*[[X<?"GPI8>*_&.
MEZ99:EXCU;Q!J[:+X+\$1:R)CH@UZXM+:YO]3U&ZCMY;A-+T^W$IMU65YHD<
M-1^@+3R.1E^*'Q>^%[:?=?''PQX,U'PEJFK:=I4WCOX53ZZMAX0EU.ZAT^SE
M\7>'O%#274>E27UQ AU.SO)DBW!9( \D8<_0++ITZ$/C[X[^)/#!^+5KHOA_
M1+R_\ ^.?A7X+T0:G>W]M9ZD_P 1M-\+W;W6JR6D4DELEI<^(70?9XY"4MP2
MK,2"?@"6QT/VS]JO_H7?V?/_  L_B/\ _,'0&A>/QIL]$O/C;)XRAM=*T/X.
MW'A.&:^T\W%W<ZFWB'P;H?B%H(;:14,MY)JNL)I]I"@4S,\ ;:SG!L%MC &O
M?M4:YY&NZ'X+^$/A;1)D2Y@\(^-M>\67?C6:U91(L5_JGA^Q_LK0=2=, VXA
MU-878I)+^[+,;>5@T7R/0/A;\5-/^)5KK]LVD:AX8\6^#-6/A_QKX1U1XKB[
MT'6!&946&_MO]'U;2KF-7DM;^#:L\:[MB'*@V^0K6/5* "@ H * "@ H * "
M@ H _!7]L?XMZG\>/V@H?@O%XMT3PI\._!_BN/PO::EK=PUKX>@\41K_ &;K
MWB7Q!>6\$KJEM?/>:="[9A@AA>0F$75S)7C8JJZU;V7,HP@[)O:^S;]-O+RU
M/ZJ\.>'Z'"O"4N)'E];'YOF&%>)E3HQYL0\-_$H8;#PE**O."A6FE[\YM1M/
MDIQ.6D_9\_9'TR?_ (1_6/VQ+1O$R$P3W>C?#G6]4\+170P&6+6+.XGL;JV1
MLJ)QJ<:N!N^3.T3[##1]UXJTEVB[?>M/Q.Z/%OB!6C]:PWAW.."?O1A6S"C2
MQ+CTO1G&%6,GOR^P;CMKN9DW["WQ(O/%VBV?A/Q%X4\5_"W7K"[UJT^-MA?P
M)X&L-%TZ-Y-0GUUHKJXDTO4(2@C%IOF61Y,).5M[I[1?4ZG,E&2E3:NJB?NV
M6]^S\O\ @VVCXHY-2R_$U,?@\5@,\PE2%&635(2^NSK5&E3C03C!5:<KW]I:
M+C%>]!.=)5/J;XY> _V;-)^#G[,'@_XD?%OQ5/HNC:7\0]-\&^/? 'A^SU'0
M=9SJ/AQO$.I:G9EK^X&GP7B6$-K]@>X,P>5\LFUEZ*T,/&EAX5*KM%24915T
M]5=O?1:6L?#<+YKQG7XBXWS#)L@PL,3B*N7U,9@<?7G3KT?W>(6'ITY_N8>T
ME!U)5/:J"@U%63NG\7?%C]G6_P#A;H.B?&;X4?$'3OBA\+GU>W&G^.O#4<^G
MZOX2UNWGMYM/@\2Z;OD?1;L73P)#.9583HB3PVDD]M'/RU*#I1C5I352FGI)
M:.+Z773^MM#])R#C"EGF*Q/#>?934R//(TI>TP6)<:E+%47&4:CPU2R5:'*I
M.<>5KD;<)U8QJ2A^UO['OQMOOCK\%='\3:]-#-XNT2^N_"WBV6%(8!=:KIB6
M\]OJ?V:!42W-]I5YI]PZQQQQ">2X6)51 J^MA:SK4DW\4=)>JZ_-6/YJ\0^&
M:7"W$F(P.%C*.7XF$,3A5)M\E*HY1E2YI-N7LJL*D(MMRY%!R;DVW]25T'PQ
M\A^#[;XES?%[]HP^!]9\#:99+XZ\(B]B\5^&M?URZDNO^%8^$"KVLVD>+-)C
MAMQ%M!22*5MP)W@':#;RL/9+R.$_:!\*_$73M/L/B%XH\7:?XF\>VGV_X>_!
MOP7X"\,W/AS3H?%'Q+M6\.:GK4C:QXDU6ZUC6K;PXVI7,*R7-M;0MIBR$(K2
M&C8%]UCA?%>J>(/!7@OX5ZGH'[.OQ,\,?\,\WEGK%AXEU>Z\*793P?';_9/B
M'::J=+U9Y=FL:$U[<7$L-L0MQ#%(%2-6P;?(/F?1O[/UTA\>_M%PWMU%=ZQJ
M7Q)TWQ997@E$IU#P%XB\):._@6[M91Q/IJ6%I=V\;)E4:"2(G<A /T!].ECV
MCXE^-]"^'7@O5_%?B*UGU#3K#['"-)LX[2?4-7O;^^M[#3],TZUO9X8KJ^GO
M+B%8XFD7)R<@*2#]!)?*Q\1?&&*XFOOVE8;2Y^Q74OQP_9BBM;SR4N?LEP^A
M_#5(;G[/*0D_E2%7\MR%;9M/!H&M+>5SZUL_!7Q=@N[6:[^-OVRUAN();FS_
M .%;>&;;[5;QRJTUM]HBNR\'FQAD\Q 67=N'(H#Y'R#\7X;M?%GQHU?<1X:\
M,_M'?LR^(O'D6<1S>#-/\"^$H]0%P?X;:'4+C2KJ1R"J)9M(V%0LIM\AKI\S
M](596561@RL RLI!4J1E64C@@C!!%!)YGX,^(WASQAXR^)GA;0M-O8[OX=:K
MHFD:_KCV]BFE:OJNHZ=+>R6>G75M<R37-SIBQ_9KM;F* Q2R*J;U.0!:QZ;0
M 4 % !0 4 % !0 4 % '\H7@[P[J/Q?^*FA>&_M\6GZI\1?&=O8R:E<1R7,-
MG>>(M4_?7DL2R*\Z1R7+R%0X9@N,Y-?-PBZM2,;\KG*U_5G]YYABZ/#N18K&
M>R=6AD^#E-4XM1<H8>E[L$[-1;44D[678^L7_P""=?QRT[4)QXDUGX;>%_#%
MI.Z7'C+5_%J0Z,MM&Y'VA(OL?VI7=5)2.XAM^1M=HP"PZ?J-9/WG&,5]IO0^
M"7C!PQ6HP^I8;,<;C9Q3C@Z6%;K<S7PM\_L[)[RA*>FL5+8^@_AUXC^%6I>"
M?B#^QC\.KJ;Q3X=M?AC\1?%/BGXM2LUK9ZU\0](?2+ZUO] T^&1U;PK:7%E%
M$)6E87,=G;>4[Q[[F^WIRIN$\)3]Z*A)N>UY*S5EV5OG^+^1S?!Y]0S/*/$?
M.(+ 8R699?AL+E27-.C@*JJPE"O4:36*J1FY<JBO9RG/F496ITOFK]I'_DV'
M]B3_ +%OXM?^GKP=6%?_ '?">D_SB?:<&_\ );^)G_81E7_IG%F#^QM>3ZCX
MD^*?PXO79_"?Q ^#'Q M/$%O)O:VM9]%T:75='UY4 *I?6%U$ZPRL/D^VOCY
MBM3A7[U2G]F=.5UZ*Z?R.KQ&IQH8/(LXI+EQ^49Q@)4)*W-*-:LJ56A?=PJQ
M:<XK?D72Y]=?\$J-9N<_&CPZPW6:#P3K,'SD>3<O_P ))8W0\O!#>=%%9_,"
MNW[+@AMPV=.6NWM8]%RM?BC\_P#'?#07^K>+6E3_ &RC)6WBOJ\X:].5N>FM
M^;I;7]@J]0_GDXKPUX'T_P ,>(O'OB.TN[R>Z^(&MZ9KFI07'D?9[*XTOP]I
M?AR&&Q\J)7\EK72H96\UI&\R1\$+A0?H'X6,KQ!\,=*\2_$;P)\1M2U+4VNO
MAY::_%H&A(UL-&^W^(K,Z?>ZO=1M 9IKY+'$46)56/:'"[LFC8-CO[^QM=2L
M;W3+Z%+BQO[2XL;RWD&8Y[6ZA>WN(7'='AD=2/1J-OD&WR/G&S_9DT72=)\#
M1Z)X^\>Z+XM^'6F3:%X<\=Z?>:2FM7'APWSWMAX8\36,NE2:;XE\/6)<106=
MW:86-=N[YF+&WR'>W2QMQ? D:QXK\-^,/B9X\\2?$G4/!EVNH^$M)OK+0_#W
MA?1]40[DUE]"\/V$"ZEK$3A3%<W<THBV#8@P"#;Y!>WD7_$7P*\/>)+KQQ=W
M6KZS _COQC\//&>HK;FQ"V=_\.;;0+72[6R\RT8_9+E/#UL;CS3(^9I?+9!M
MVFWR"]OD>WT"/.[/X9^'K?6/B?J=Z)=7M_BM+I+>)-'U)+>731;Z5X4L?"/V
M*"-(E=K:XTZP5Y1,\AWROM*KA0?H&WR/.-+^!OBOPSI \*^$/CM\1=#\(0Q/
M:V&E7FG>#/$&JZ)I[JT:Z=HGB;5O#TE_:6D$)6*W\]KJ2W2-!%(K(&HV^0[^
M6QZI\/?A[X9^&'AFT\*^%K66*R@EGN[R^O91=ZSKFJWDAFO]:U[4C&CZGJ]U
M*=TEQ(!PJ1H$BBCC0V\K".WH * "@ H * "@ H * "@#^;KX=>"[GX=?MM^$
MO!%U"8&\-?'/3M-MU/ DTZ/Q$CZ5<Q_],KC3)+2=. =DRY / \&G#V6+C#;E
MJ)?*^GX']E9OF4,W\,\?F=.7,L9DE2I)]JCP[56+\X5%.#\XL]T^.W[#W[0O
MCCXT_$3Q9X5\.:'JOAOQ7XSU[6-.U5/%F@VL<%K>W\TJQWUK>WD-W%<Q,6BE
MCCMYMLD3J"P&3M6P=>56<HQ3C*3:?,N_WZ'RW"WB=PCE?#63X#'8RO0QF P=
M"C4I/"UY-RA32O"4(2IN,OBBW.-XM/38X'6#\//V6OA;X_\ !&D>,-+\;_M&
M?$?3)O!'BN_\)W$M]X5^''@JZN;:77_#\.KO:PQW^N7R6CVET(F=XI-@*6XL
M@VHP^3#4YP4E*O-<K<=H1ZJ_=VL_TMKZV&6;\<YYE.9XC+JF5\'Y-4CC<+3Q
M453Q688R$9*A7=)2DZ="DY*I2<DE*-[.I[2U'F_"WP&^/'QU^%OP^U!?'7@&
M;X?^%XO$5GX6T[Q+XTTG2I/!EO-J@M]934+..R:XLUNKC2+>X"RM.YA$$@"K
M)@S&C6K4X>_'DC?E3DERZZZ=-CLQW%7"O"V>9M1_LO'1S;&O#SQ-3#X.K56,
ME&ES473FYJ$^2-64&XJ*4^:-VXFWJNN?"7]F[X7>,O!7@'QCIWQ*^._Q$TF?
MPAXO\;^%C/<>"?!W@Z_FBDUK0?#.K7$,2ZQ=7UO;QV\EW;HV3,7+V[6B0S4W
M2P].4(24ZTURRDOAC'JD^M^Z_"QS8?"Y_P 99YEV99KEU3)>%<GJQQ>$P6)Y
M8XS%XNFFJ-?$THN3HQI2DYQIS:M;EM4524X_9_\ P2W\$W&E_#WXB^/+F#RU
M\6^)=,T/3I''SS67A.RNI9YX3CBW>_\ $-Q"2"-TFGN"/W:FNK+H<L)SVYFD
MO^W?^'_ _-_'',X5LWR?*H2YGE^&J5JB6RGBIQ48O^\J>'C+RC-6W9^I->B?
MAI^7ND^'_BU\=_VK/VN?!\7[27QB^%_A7X0:O\';3PKH'@&[\,Q:>D7C/X>#
M5]6$Z:YX?OW!&H:<TR>6Z?->S[LY7: ,^&_BGXW_  :_;CT+]FO7/C=KGQY^
M'7C?X4ZM\09QXRTO0O\ A,OAW=Z>^H6]K)?ZOH=C;F6SO+O2HHHUE$,3+K48
M%K')$MQ> 'D?PG_:T^,5A^QM/KR^(9_&_P >_B=^TGK7P%^#]WXE^S7,-KK_
M (@U.SM-&N+^/R!%_9.C:<FHW0,T,L/G+;1SAHIF!-@V/I<_L<_&Z+P:^IP?
MMM_M"2?'%+)KZWUZ;7M,3X1OXB5EGCLY_A:=$G@'ADR+Y#(+EY0',Q5XQ]B8
M ^7?&7[?GQ<?]D2\U.6#3/A_\=_#_P >[3]F7XK>,8]/2_\ #_P\U*)+^XU7
MXE0:6T5S!Y,MGILEHL,H,,5^UVT*E(K6*4 ]T\=?LZ?'[PO\/M.^*7[+O[6?
MQK^*7Q!TN#3M?M?#GQ$\;^'/'/PW^+&GGR7NM-TRTN+>RTOP\EY$TLMM<PW<
MD7ECR/-CDD2^MS;Y!M\CJ?VAOB=\>/'OQ<^%7[+?P)U8_"OQ5XJ\ M\5_C5X
MZGM-*UK4_AM\/'U"/08=/T/SS-;7/B.XUN+4;$/;@R+(;&6&6&"2:ZMC] _0
MR/B7^SO^TS\'=*TWXA_LU?M#_&OXI^)O#5]:7GB3X3?&[Q;I'C?1_B3HZWEL
M+W2]&OM2TNPB\)ZF;5KLEX6C$B;1!-:30JUP;?(-OD4=:^,?Q-7]J;]ISPG'
MXDU_2/#/A7]C-/B'X;\)SRVGE^%O&DEI:S-J<:P"1%U>"21XW99I8]RMMW#!
M(!F?LZ_!+XQ?&/X&_"[XI:Y^V9^T?I>K^.O"&E^(M1T[2;_P,--L[J^C+R06
M0O/!TTP@4CY?-ED;U8T <W^VOJ?[1?P1\#?LM_#CX*?&+QIXA^)'BCXIZUX=
M_P"$I\67.B'6?'=S=FYUK1=%\2O;Z3!I\MI'/=V^F1*+:",P6\"SO_K)2;!L
M?5F@_M&Z5\:/V1O'GQE\ W\FB^(]*^%_CUM9TV-O+UGX??$GPYX/OKO5-!OX
M)@9+74=,U589H3,BF:"2TN0OEW"Y /EFY^,_[07Q/^'W[''P'^#WCZ+PO\7_
M (Q? SPY\7/BQ\7=;TVSUF^\-> [/P_I-IJ>JV5C<VLD5UX@UOQ'?7,43I'"
MT<MJBK-:BY-U:GZ!^AWGQ0_9Y_:9^#?ANT^(W[-/[0?QN^+7C_PY?:=/K7PN
M^-GBW2/&OA/XBZ1-<16^K66GV]YI^EIX8U)1,UTKVU[;@06\D5O)!-Y;L;?(
M-OD<1K^K?&?XV?MPWOP<B^,7Q7^!'A>U_9;\,_%JX\+>"[_PTU_I'BZX\1>'
MM(U'1]0FU#2=2M)VB7Q#<Q3R6^0\NFQ-%)Y9.\ ^J/"?P/\ 'OPDU"\^(.H_
MM%?'_P",]OX:T#Q#?+\-O$MUX-GT[Q-<QZ->FULHXM,\,6,[:E]H$9M0+E%^
MT"+?E,@FP;'Q]^S+X4\;?MB_"*;XSZW^V=\9M!^)GB+4/$$C^#_A'XSTCP]X
M(^$DL.IWMKX>\.ZOX M]*^T:G+%9VUM<S'4KJW>]M[J(12[LZA=@'T=X6TO]
MKR__ &7O%O@_QK-,OQY\-ZOXT\)>'?&6EZKX?T2Y\?Z/IJW<7@'X@VUQIUV;
M;18KF[N-(GN[>Z-K=RVNC7JS6_GW@CG/P&K)^AV/AGPO^U%!H&DP_P#"8Z98
M2PV<45U#XI:SU;6IK^/*:CJ$]W%9ZH([2^OEN+VTM&O[A[.SO+6TD*R6S(AM
M\A^[VV,GXU?LPVGB;XV?"3X\^#K01>*O#OC[P<WCRU6:*&'6O"^GW<,*ZVJ2
MD!M7TN"*VC8*P,]DA #26D22\E7#J56E6@K2C*/,NZ77U7Y>A^C<-<;5,#PU
MG_"N85+X#%X'%K RLW*CB:D&_8W6U*NW)JZ]RL^D:DG'\4OVG-2U&V_:#^-M
MI;W][!:O\2?%A>VANIXK=]^J3A]\*2!&W  '(YP,UY.(;5>JKV7/+3YG]*\$
MT:,N$>&9RI0E..786TG&+DK4HVLVKJW0^>:Q/K@H ]O^ ?P*\7_'OQYIGA/P
MY97::4EU:2^*_$BP%M/\,Z$TP%W?7$[XB:]:!9A:6A</<S*%4!%D>+:C1E6F
MHQ5DMWT2_K9=3YGBOBC+^%,JKX_&58>W<9+"X=RM4Q%=+W(1BO>4%*SJU+<M
M.&KU<8O^E_X=?#_PU\+/!7A_P#X/M'L_#_ANR%G9),ZRW4[O+)<WE]?3+&BS
MW]W>SW%S/(J(K2W#E41<*OO4X1I0C3@K1CL?Q9G&;8W/,RQ>:YA453%XR?/-
MI6C%)*,(0BVW&%.$8P@FVU&*NV[M]K5GFGXR6/P]_9E\<_MJ?MP/^T+KFCZ/
M-IFM_ E?"8U7XQ>)?A4;B*[^%B'6C!'X?\;: -<"-;:7N:<71M_,4(8OM+>:
M 9GA33_A)\(/V]O@=X7_ &-_%\?B;1/B5H'C3_AH3P[HOCBZ^*FA:=H.BZ6;
MCPUJVH^)=5U36+S2-06\$KA)-7W!K+3HS$J:@([TV#8^??A-H>IZ7^R/\+?C
MSINF7^M6G[.'[<>O_$?QAI>GVIOI_P#A79U'3;#Q?JD%G$C3376G1?8+D/&"
M(85NIY%V0%XS;Y!M\C]MW_:C_9RC\%R_$+_A=_PP?PA#8OJ#ZM!XRT.<^7'#
MYS6J:?#>->OJV,1_V:MN;SSB(/(\X^70!^2/PI^(&J_#?X8?$GXY_&#X&_V_
M\#OVPOVL-5O?&\'B[2KI=/\  /P?\07D,NA?$/6O#0T.]-SI3W=]J0CN+A(/
M/?3+">*X>74+22<V\@V\CU?XU?!O]B_X3_";QI\7/V?/CH?@=XLT7PQK7B;P
M9/\ "7X^7DNC^+?%5CIT]YH&B2>$KGQ)JMMKUKJ6HQVME)8:?;PF2.Y8$;0U
M&WE8-O*Q-I?Q9UWX-?M)_LY_'[]HFPD\(Z%^T7^R7X-^&/C#Q??VJ:;H?@SX
MP6.KQ^+YH/$C)B'PU8WUM/ #%<B,6TEY.SF.VTN\>W/T#]#Z_P#VE/VPO 7P
MB^&E]J'P]\6^"/'WQ<\1+:Z/\(_A]I%^/&5[XQ\6:I=6UGIEN=$\)ZFM[-I*
MM<B6:<7-FC!%ACN/M%Q!'* ?(>HOKDO[7W[6<OB:*Q@\22?\$^+-_$$&F+(N
MFPZX^F:>VK1:>LUS<2+8I?FX6$/<3L(PFZ1SEF .<_9;^"O[!&N?L\?!_6/B
M)XM\,67CC4/ ^CW7BBUN_P!IWQWX3N;?5Y(B;J.;PWIWQ7T^VT:16QFUALK9
M$Z"-: /2OVDK/X>:9XG_ ."<&D?"G5=-UCP%HW[2NF:5H%YI7BJY\;6GD61M
MXYH/^$FO=6U.YU2:&Y\Z-WN+ZXE5E*,V5P#;Y!M\CF/VM]$/['.M_%/XK^$=
M+U9_@;^U#X,\?^"_C/H&FQB[T_P5\8=<\,:K;^!/B-IE@NQK&TUW4KV\L-4*
MMY?F7+RD23RV-LIL&QR7PY\7Z3^SYXN_8)^/?Q N&T3X4^/?V)?"O[/VL^,K
MFWN9]#\)>)8CH?CW0&UJ>WBD&D1:G*!;K=2JD8CM;J65U@LYI(C;Y!M\C[D_
M::_;!\%_"7X2ZEX@^%_BKP%\1OBMKC:5I/PI\!:1JD?C2\\8^(=9U"TMK5(=
M \(:LNI:AIL=G+<7+R6\\"MY,<23>=<0I* ? FO>&OAU\1/V_D@_:WG\.^%9
MY?V*_ FM^(+9/B)XB^%>A67Q0?Q!X435=+TG6M*\9Z;?3VD+WWB1(--N-6O@
MT-OYLGGR6BSQGZ!^A]E^$_"'[+/P>B\7^-OV77\.?$7XRZ=X#\52>&/ 6G?M
M%^+O'6H^+VL;#^V9- L=$USX@>((4N;J32H$6ZBTV2:+D*ZH[[C8-CQ'P#X"
M_P""?_[2?@[3/C+=6W@WX)?%?5[(W?CV#P3\5;[X5^,/ GC .Z>)=.U33;+6
MM)B2>/5HKEA>W^BH;M0EU@F8F@#UK_@G_P".O'WB5?C]X2U#QGK?Q8^#?PT^
M)G_"+? [XQ>);P:QKGC31(QJBZ]ID_B9$2/Q=::));:,L6LHKBX;5YPDI@BA
MAM@#]%* "@#Y0^./[&GP8^.EY+KNM:;?>&/&$JJ)O%?A.:WL+Z_\L8C_ +9L
MKFVN+'56 PIGDMUNMB(@N51%5>:MA:5;5KEEWCI]ZV?Y^9][PQXC<2<+4XX7
M"UH8W+H_#A<4I3A3OO[&<90JTN_*INE=N3IMML^ _&/_  30M?#MY&ME\99Y
M+6Y93!%=> (WN((W:50LMQ%XRC2X<>5]Y8(0=WW1CGBE@.5Z5=/\/_VQ^KY=
MXTSQ=-^TX<C&=->\XXYJ+:MM%X-N*UV<I>IZSX"_X)>_#ZTDL]0\<?$?Q+XK
MMBJ3_P!F:+I%EX1MYB2&6&ZN);_6+AH-O#>1);.>JR)TK6&7P5N>HY>27+_F
M>!FOCAF\U4HY7DV&P$TW'VE:K/%R72\8J&&@I7U7-&<5LXL_2;P/X%\)_#?P
MSIG@_P $Z)9>'_#VD0+#:6%E&1E@JK)=7<[EI;[4)BH>:[N'EFF<EY'9B37?
M"$:45""Y8QV7]?F?C.9YIC\XQM;,,SQ,\7BZ[O.<WYZ1A%6C"G':%."C""TC
M%(ZRJ. * /*O$7P)^!_B[6;WQ%XL^#?PJ\3^(-2:%M1UWQ%\//".M:S?M;6\
M-G;M>ZGJ6CS7-TT5I;V\"&65ML<$:+A44  Z'P?\./AY\/8KN#P!X"\&>!X;
M]D>^A\'^%]#\,Q7CQY$;7<>BV-LMPRACM,@8C)QUHV\@V\C1\.>#_"7@[3)M
M%\(^%O#GA71I[JZOI])\.:)IFAZ9-?7VW[;>36&F6L$$EU<;5\V5D+R;1O)Q
M1MY!MY'D2_LH_LRQ^)U\9)\ OA&GB6.19TU)/ /AM2EVCF5;];1=/%J-2$IW
M_;/)^T;@&\S(!!MY6#;RL>ZWEA8ZC97.F:A96E_IUY;2V=YI]Y;PW5E=6D\9
MAFM;FTG1HI[:2)F1XG5E96*D$'% 'A?A[]E/]FCPGXB/BSPY\!OA/H_B);B.
M[M]4LO WAZ.?3KN*9KB.ZTA#8F+1KE96R);%+=QA1G:J@&WE8-O*Q[1KWA_0
M?%&DWN@>)]$TCQ%H6I1>1J.B:]IMEJ^DW\!(8PWNFZA#+;W46Y5.R6-AD XX
MH \J^'W[-OP!^%.J3ZY\.O@]\//!^MSR/*VLZ+X7TJVU:'S RO#9ZB;=KC3[
M4JS#[-:R0P\_<HV\@V\CT2;P/X+N-8U?Q%/X0\+S^(-?T4^&]>UR;P_I,FL:
MUX=( .@:OJ;VAN=2T7"@?8;B22#@?N^* /-_^&9/V;?^C?/@A_X:?P'_ /*"
M@#L;+X4?"W3++PYINF_#7P!I^G>#=5EUWPC867@[P[:67A76YY6GFUGPY:P:
M<D6AZK).S2-=V2P3,[%BY)S1MY!MY'4Z[H.A>)](OM \2Z+I/B'0M4A^SZEH
MFNZ=9ZMI&HVX=9/(OM-OX9;>[A\Q$;9+&ZY13C(% %"7P9X/G\,1>"9_"GAJ
M;P9!IUOI$/A&70M+D\,0Z3:1)!:Z7%H#VIL8].AACCCCME@$2+&JJH"@  \X
M\ _LV_ 'X6:W/XD^'?P<^'/@[Q#.TQ_MS0O">D66K6Z7 =9[?3[]+7SM,LY%
M<JUM9O!"5"J4PJ@&WD&WD=#XJ^"_P=\=ZK_;OC?X3_#3QEK?V:&S_MGQ5X$\
M+>(=5^R6Q<V]K_:&KZ5<7'V:(R2%(O,VKYC;0-QR?H'Z$7AGX(?!;P3K%OXA
M\&_"'X7^$=?M$GBM=<\,^ /"F@:Q:Q74+VUS';ZGI6DP7,*36\DD4BI(H='9
M6RK$$V\@V\CF?&7[+_[.GQ!\0KXK\;?!#X7^)O$GVG[7<:WJW@S0KG4=2GV&
M,-K5R;,-KJ!3Q'J'VI 0"%R 0;!L>QZ-HNC^'-+L=#\/:3IFA:+I<"VNFZ/H
DUA:Z7I>G6R9*6UCI]C%%!:0*2<1Q1HHR<"C;RL&WE8TZ /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
